Short squeeze! , Also, I think the Prostate cancer trial will have positive results. Roche will probably make a buyout offer.
Todays WSJ has a small article saying the Norfolk Southern cancelled the rule and they will talk to the oil shippers and come up with a different plan. No matter what it will cost the ND drillers more to get the oil to market.
Title - Norfolk Southern- Legal Protection Required Against Older Tank Cars
This railroad has become the first big American freight railroad to require its customers to give the railroad legal protection against damages from fires, explosions, or release of hazardous materials.
This applies to all except CPC-1232 cars produced after late 2011. Only 14,000 of the 94,000 current tank cars meet this standard. Now 85% of the tank cars hauling oil don't meet this standard.
Norfolk Southern is not that big in oil but if BNSF or CSX or the US Transportation Dept. follow suit, then look out below.
Since Warren Buffet owns BNSF he has an important decision to make.
I have a technical degree and I did work in an academic cancer research lab for twelve years. I was an early investor in Seattle Genetics, the number one company in antibody drug conjugates. I think the new ADC products from IMMU are very promising. However, you are correct that the company has a great need for cash.
Will they get a good price for IMMU 132 or will somebody pick it up cheap when they run out of cash ?
The Nektar drug seems to have more extensive trial data in regards to heart problems which were not found. The FDA may still ask PCGNX to produce more trial data which will take a long time.
I was a Medarex stock holder and I made a few dollars on the BMY buyout. However, BMY got MEDX very cheaply so if they go after CLDX it won't be for big bucks.
Dr. Goldenberg said the reason they have not concluded a partnership deal for IMMU-132 is that they are waiting for more results (good hopefully) so they can get a better deal.
I made money on MEDX and I am long on IMMU. I hope the 132 data are good. By the way, BMY would be the perfect buyer for IMMU. They have lots of antibodies from MEDX and they would be a good fit for IMMU's dock and lock technology.
IMMU will present the 132 data in Pancreatic cancer at a meeting on May 18. If the data were any good the company would wait another 3 weeks before announcing a stock offering.
The ALS drug has been written off. The only thing left is the heart drug. Only a piece of good news on OM will get the stock to go up.
This applies to all the Bakken producers. Suppose this happens: The current unmodified railcars that are transporting 70% of the ND oil are not permitted to do it until they are modified for safety reasons. There would be a temporary backup of 0il leaving ND and a loss of income for the producers.
All the biotech stocks I watch are down today including SGEN which has a product generating good sales.
Also, the AACR abstracts are available on line and I have read the abstracts of the four IMMU presentations.
This company does have some good potential products and they should be able to find a partner or get bought out.